KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-cash Items (2016 - 2018)

Teva Pharmaceutical Industries filings provide 9 years of Non-cash Items readings, the most recent being $24.1 million for Q4 2018.

  • On a quarterly basis, Non-cash Items rose 225.49% to $24.1 million in Q4 2018 year-over-year; TTM through Dec 2018 was $24.1 million, a 225.49% increase, with the full-year FY2018 number at $24.1 million, up 225.49% from a year prior.
  • Non-cash Items hit $24.1 million in Q4 2018 for Teva Pharmaceutical Industries, up from $7.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $402.4 million in Q4 2015 to a low of $7.4 million in Q4 2017.
  • Median Non-cash Items over the past 5 years was $14.5 million (2016), compared with a mean of $92.2 million.
  • Biggest five-year swings in Non-cash Items: surged 3085.72% in 2015 and later crashed 96.4% in 2016.
  • Teva Pharmaceutical Industries' Non-cash Items stood at $12.6 million in 2014, then surged by 3085.72% to $402.4 million in 2015, then crashed by 96.4% to $14.5 million in 2016, then plummeted by 48.85% to $7.4 million in 2017, then soared by 225.49% to $24.1 million in 2018.
  • The last three reported values for Non-cash Items were $24.1 million (Q4 2018), $7.4 million (Q4 2017), and $14.5 million (Q4 2016) per Business Quant data.